A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Jonathan Welte
Advertisement
With Simon-Kucher & Partners’ life sciences division
Articles by Jonathan Welte
Advertisement
Latest Updated Articles
China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global InvestmentPublished: June 20th 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
2
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
3
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
4
Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics
5
